Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Castle Biosciences(US:CSTL) Globenewswire·2025-12-09 12:00Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanomaFRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent expert consensus paper titled “31-Gene Expression Profiling for Cutaneous Melanoma: An Expert Consensus Panel,” which endorses the Company’s DecisionDx-Melan ...